BOFA Slaps Salesforce with Underperform Rating Stirs Debate
Bank of America initiates coverage on Salesforce with an Underperform rating and a $160 price target, highlighting un...
Learn how to choose a low-fee Dividend Aristocrats ETF and what fees to watch. This intro covers cost factors and quick tips for a cost-efficient selection.
24,603 articlesBank of America initiates coverage on Salesforce with an Underperform rating and a $160 price target, highlighting un...
Taxing wealthy harder than it looks sounds simple: just raise rates on big earners. In practice, money moves, lawyers...
Long-term holders in NVDA, AMD, and LLY are posting outsized gains as AI and GLP-1 drug momentum persists. Traders wh...
NVIDIA faces a supply bottleneck at its chipmaker that could cap near-term revenue even as AI demand remains strong. ...
Investing in early-stage biotech requires a steady playbook. This article breaks down Lantern Pharma (LTRN) in 2025, ...
As whispers of an OpenAI IPO grow louder, investors must ask: is openai going public wrong for reasons that could der...
Rigetti Computing stock surged as government funding boosted optimism for quantum tech. Learn what happened, what it ...
The United States appears to be nearing a practical ceiling in its sanctions campaign against Iran, raising questions...
Lemonade is betting big on AI to transform how people buy insurance and file claims. This article digs into what lemo...
Investors chased space-focused stocks higher on SpaceX IPO speculation, lifting Spacemobile 20%, Planet Labs 15%, and...
XRP eased lower toward a critical support level as sellers held sway, signaling thinning upside momentum for the near...
Novo Nordisk is gaining ground on Lilly in the obesity pill market. This article breaks down the drivers, the competi...